A Vaccine Against Group B Streptococcus: Recent Advances

References

• O’Sullivan CP, Lamagni T, Patel D, et al. Group B streptococcal disease in UK and Irish infants younger than 90 days, 2014–15: a prospective surveillance study. Lancet Infect Dis. 2019;19(1):83–90. doi:10.1016/S1473-3099(18)30555-330497953
   PubMed Web of Science ®Google Scholar
• Sigaúque B, Kobayashi M, Vubil D, et al. Invasive bacterial disease trends and characterization of group B streptococcal isolates among young infants in southern Mozambique, 2001–2015. PLoS One. 2018;13(1):e0191193. doi:10.1371/journal.pone.019119329351318
   PubMed Web of Science ®Google Scholar
• Seale AC, Bianchi-Jassir F, Russell NJ, et al. Estimates of the burden of Group B Streptococcal disease worldwide for pregnant women, stillbirths, and children. Clin Infect Dis. 2017;65:S200–19. doi:10.1093/cid/cix66429117332
   PubMed Web of Science ®Google Scholar
• Raabe VN, Shane AL. Group B Streptococcus (Streptococcus agalactiae). Microbiol Spectr. 2019;7(2). doi:10.1128/microbiolspec.GPP3-0007-2018
   PubMed Web of Science ®Google Scholar
• Madrid L, Seale AC, Kohli-Lynch M, et al. Infant Group B streptococcal disease incidence and serotypes worldwide: systematic review and meta-analyses. J Infect Dis. 2017;65:S160–72. doi:10.1093/cid/cix656
   Web of Science ®Google Scholar
• Russell NJ, Seale AC, O’Driscoll M, et al. Maternal colonization with Group B Streptococcus and Serotype distribution worldwide: systematic review and meta-analyses. J Infect Dis. 2017;65:S100–11. doi:10.1093/cid/cix658
   Web of Science ®Google Scholar
• Lawn JE, Bianchi-Jassir F, Russell NJ, et al. Group B Streptococcal disease worldwide for pregnant women, stillbirths, and children: why, what, and how to undertake estimates? Clin Infect Dis. 2017;65:S89–99. doi:10.1093/cid/cix65329117323
   PubMed Web of Science ®Google Scholar
• Unicef; World Health Organisation; The world Bank; United Nations. Levels and Trends in Child Mortality. Report 2019; 2019.
   Google Scholar
• Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease–revised guidelines from CDC, 2010. MMWR Morb Mortal Wkly Rep. 2010;59(RR–10):1–36.20075837
   PubMedGoogle Scholar
• Le Doare K, O’Driscoll M, Turner K, et al. Intrapartum antibiotic chemoprophylaxis policies for the prevention of Group B Streptococcal disease worldwide: systematic review. J Infect Dis. 2017;65:S143–51. doi:10.1093/cid/cix654
   Web of Science ®Google Scholar
• Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. Vaccine. 2013;31:D20–D26. doi:10.1016/j.vaccine.2012.11.05623219695
   PubMed Web of Science ®Google Scholar
• O’Connor KA. Group B Streptococcal disease in the era of intrapartum antibiotic prophylaxis. Clin Pediatr (Phila). 2007;40(6):361. doi:10.1177/000992280104000614
   Google Scholar
• Castanys-Muñoz E, Martin MJ, Vazquez E. Building a beneficial microbiome from birth. Adv Nutr. 2016;7(2):323–330. doi:10.3945/an.115.01069426980815
   PubMed Web of Science ®Google Scholar
• Kerr CA, Grice DM, Tran CD, et al. Early life events influence whole-of-life metabolic health via gut microflora and gut permeability. Crit Rev Microbiol. 2015;41:326–340. doi:10.3109/1040841X.2013.83786324645635
   PubMed Web of Science ®Google Scholar
• Kumar M, Singh P, Murugesan S, et al. Microbiome as an immunological modifier. Methods Mol Biol. 2020;595–638.31502171
   PubMedGoogle Scholar
• Thwaites CL, Beeching NJ, Newton CR. Maternal and neonatal tetanus. Lancet. 2015;385(9965):362–370. doi:10.1016/S0140-6736(14)60236-125149223
   PubMed Web of Science ®Google Scholar
• Madhi SA, Cutland CL, Kuwanda L, et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med. 2014;371(10):918–931. doi:10.1056/NEJMoa140148025184864
   PubMed Web of Science ®Google Scholar
• Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet. 2014;384(9953):1521–1528. doi:10.1016/S0140-6736(14)60686-325037990
   PubMed Web of Science ®Google Scholar
• Davies HG, Carreras-Abad C, Le Doare K, Heath PT. Group B Streptococcus: trials and Tribulations. Pediatr Infect Dis J. 2019;38(6SSuppl 1):S72–6. doi:10.1097/INF.000000000000232831205250
   PubMed Web of Science ®Google Scholar
• Bardají A, MacDonald NE, Omer SB, Aguado T. Maternal immunization: a call to accelerate progress. Vaccine. 2019;37(22):2882–2883. doi:10.1016/j.vaccine.2019.04.03131014962
   PubMed Web of Science ®Google Scholar
• Vekemans J, Moorthy V, Friede M, et al. Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics. Vaccine. 2018.
   Web of Science ®Google Scholar
• Heath PT. Status of vaccine research and development of vaccines for GBS. Vaccine. 2016;34(26):2876–2879. doi:10.1016/j.vaccine.2015.12.07226988258
   PubMed Web of Science ®Google Scholar
• Dangor Z, Lala SG, Kwatra G, Madhi SA. Group B Streptococcus: developing a correlate of protection for a vaccine against neonatal infections. Curr Opin Infect Dis. 2016;29(3):262–267. doi:10.1097/QCO.000000000000026626926474
   PubMed Web of Science ®Google Scholar
• Fabbrini M, Rigat F, Rinaudo CD, et al. The protective value of maternal Group B Streptococcus antibodies: quantitative and functional analysis of naturally acquired responses to capsular polysaccharides and pilus proteins in European maternal sera. Clin Infect Dis. 2016;63(6):746–753. doi:10.1093/cid/ciw37727402816
   PubMed Web of Science ®Google Scholar
• Dangor Z, Kwatra G, Izu A, et al. Association between maternal Group B Streptococcus surface-protein antibody concentrations and invasive disease in their infants. Expert Rev Vaccines. 2015;14(12):1651–1660. doi:10.1586/14760584.2015.108530726364978
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). WHO preferred product characteristics for Group B Streptococcus vaccines. 2017;18 Available from: http://www.who.int/immunization/documents/en/. Accessed 316, 2020.
   Google Scholar
• Rajagopal L. Understanding the regulation of Group B Streptococcal virulence factors. Future Microbiol. 2009;4(2):201–221. doi:10.2217/17460913.4.2.20119257847
   PubMed Web of Science ®Google Scholar
• Herbert MA, Beveridge CJE, Saunders NJ. Bacterial virulence factors in neonatal sepsis: group B streptococcus. Curr Opin Infect Dis. 2004;17:225–229. doi:10.1097/00001432-200406000-0000915166825
   PubMed Web of Science ®Google Scholar
• Vornhagen J, Adams Waldorf KM, Rajagopal L. Perinatal Group B Streptococcal infections: virulence factors, immunity, and prevention strategies. Trends Microbiol. 2017;25:919–931. doi:10.1016/j.tim.2017.05.01328633864
   PubMed Web of Science ®Google Scholar
• Nuccitelli A, Rinaudo CD, Maione D. Group B Streptococcus vaccine: state of the art. Ther Adv Vaccin. 2015;3(3):76–90. doi:10.1177/2051013615579869
   Google Scholar
• Korir ML, Manning SD, Davies HD. Intrinsic maturational neonatal immune deficiencies and susceptibility to group B streptococcus infection. Clin Microbiol Rev. 2017;30:973–989. doi:10.1128/CMR.00019-1728814408
   PubMed Web of Science ®Google Scholar
• Rosini R, Margarit I. Biofilm formation by Streptococcus agalactiae: influence of environmental conditions and implicated virulence factor. Front Cell Infect Microbiol. 2015;5. doi:10.3389/fcimb.2015.00006
   Web of Science ®Google Scholar
• Di Xia F, Mallet A, Caliot E, Gao C, Trieu-Cuot P, Dramsi S. Capsular polysaccharide of Group B Streptococcus mediates biofilm formation in the presence of human plasma. Microbes Infect. 2015;17(1):71–76. doi:10.1016/j.micinf.2014.10.00725448634
   PubMed Web of Science ®Google Scholar
• D’Urzo N, Martinelli M, Pezzicoli A, et al. Acidic pH strongly enhances in vitro biofilm formation by a subset of hypervirulent ST-17 Streptococcus agalactiae strains. Appl Environ Microbiol. 2014;80(7):2176–2185. doi:10.1128/AEM.03627-1324487536
   PubMed Web of Science ®Google Scholar
• Derré-Bobillot A, Cortes-Perez NG, Yamamoto Y, et al. Nuclease A (Gbs0661), an extracellular nuclease of Streptococcus agalactiae, attacks the neutrophil extracellular traps and is needed for full virulence. Mol Microbiol. 2013;89(3):518–531. doi:10.1111/mmi.2013.89.issue-323772975
   PubMed Web of Science ®Google Scholar
• Boldenow E, Gendrin C, Ngo L, et al. Group B Streptococcus circumvents neutrophils and neutrophil extracellular traps during amniotic cavity invasion and preterm labor. Sci Immunol. 2016;1(4). doi:10.1126/sciimmunol.aah6817.
   Web of Science ®Google Scholar
• Kothary V, Doster RS, Rogers LM, et al. Group B streptococcus induces neutrophil recruitment to gestational tissues and elaboration of extracellular traps and nutritional immunity. Front Cell Infect Microbiol. 2017;7. doi:10.3389/fcimb.2017.00019
   Web of Science ®Google Scholar
• Amulic B, Hayes G. Neutrophil extracellular traps. Curr Biol. 2011;21:R297–R298. doi:10.1016/j.cub.2011.03.02121549944
   PubMed Web of Science ®Google Scholar
• Ferrieri P, Flores AE. Surface protein expression in Group B streptococcal invasive isolates. Adv Exp Med Biol. 1997;635–637.9331732
   PubMed Web of Science ®Google Scholar
• Slotved HC, Kong F, Lambertsen L, Sauer S, Gilbert GL. Serotype IX, a proposed new Streptococcus agalactiae serotype. J Clin Microbiol. 2007;45(9):2929–2936. doi:10.1128/JCM.00117-0717634306
   PubMed Web of Science ®Google Scholar
• Berti F, Campisi E, Toniolo C, et al. Structure of the type IX Group B Streptococcus capsular polysaccharide and its evolutionary relationship with types V and VII. J Biol Chem. 2014;289(34):23437–23448. doi:10.1074/jbc.M114.56797424990951
   PubMed Web of Science ®Google Scholar
• Teatero S, Athey TBT, Van Caeseele P, et al. Emergence of serotype IV group B streptococcus adult invasive disease in Manitoba and saskatchewan, Canada, is driven by clonal sequence type 459 strains. J Clin Microbiol. 2015;53(9):2919–2926. doi:10.1128/JCM.01128-1526135871
   PubMed Web of Science ®Google Scholar
• Ferrieri P, Lynfield R, Creti R, Flore AE. Serotype IV and invasive group B streptococcus disease in neonates, Minnesota, USA, 2000-20101. Emerg Infect Dis. 2013;19(4):553–558. doi:10.3201/eid1904.121572
   Web of Science ®Google Scholar
• Puopolo KM, Madoff LC. Type IV neonatal early-onset group B streptococcal disease in a United States hospital. J Clin Microbiol. 2007;45(4):1360–1362. doi:10.1128/JCM.02487-0617267636
   PubMed Web of Science ®Google Scholar
• Martins ER, Pessanha MA, Ramirez M, et al. Analysis of group B streptococcal isolates from infants and pregnant women in Portugal revealing two lineages with enhanced invasiveness. J Clin Microbiol. 2007;45(10):3224–3229. doi:10.1128/JCM.01182-0717699641
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Vekemans J, Baker CJ, Ratner AJ, Le Doare K, Schrag SJ. Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries. F1000Research. 2016;5:2355. doi:10.12688/f1000research27803803
   PubMedGoogle Scholar
• Bröker M. Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and Cross Reacting Material 197 (CRM197) when used as carrier proteins in glycoconjugates. Hum Vaccin Immunother. 2016;12:664–667. doi:10.1080/21645515.2015.108604826327602
   PubMed Web of Science ®Google Scholar
• Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine. 2003;21:3468–3472. doi:10.1016/S0264-410X(03)00353-012850362
   PubMed Web of Science ®Google Scholar
• Baker CJ, Paoletti LC, Rench MA, Guttormsen H, Edwards MS, Kasper DL. Immune Response of Healthy Women to 2 Different Group B Streptococcal Type V Capsular Polysaccharide–Protein Conjugate Vaccines. J Infect Dis. 2004;189(6):1103–1112. doi:10.1086/jid.2004.189.issue-614999615
   PubMed Web of Science ®Google Scholar
• Baker CJ, Paoletti LC, Wessels MR, Guttormsen HK, Rench MA, Hickman ME. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis. 1999;179(1):142–150. doi:10.1086/3145749841833
   PubMed Web of Science ®Google Scholar
• Baker CJ, Paoletti LC, Rench MA, et al. Use of capsular polysaccharide–tetanus toxoid conjugate vaccine for Type II Group B Streptococcus in Healthy Women. J Infect Dis. 2000;182(4):1129–1138. doi:10.1086/jid.2000.182.issue-410979909
   PubMed Web of Science ®Google Scholar
• Kasper DL, Paoletti LC, Wessels MR, et al. Immune response to type III group B streptococcal polysaccharide- tetanus toxoid conjugate vaccine. J Clin Invest. 1996;98(10):2308–2314. doi:10.1172/JCI1190428941648
   PubMed Web of Science ®Google Scholar
• Madhi SA, Koen A, Cutland CL, et al. Antibody kinetics and response to routine vaccinations in infants born to women who received an investigational trivalent Group B Streptococcus Polysaccharide CRM197 -Conjugate Vaccine during Pregnancy. Clin Infect Dis. 2017;65(11):1897–1904. doi:10.1093/cid/cix66629029127
   PubMed Web of Science ®Google Scholar
• Buurman ET, Timofeyeva Y, Gu J, et al. A novel hexavalent capsular polysaccharide conjugate vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization. J Infect Dis. 2019;220(1):105–115. doi:10.1093/infdis/jiz06230778554
   PubMed Web of Science ®Google Scholar
• Fabbrini M, Rigat F, Tuscano G, et al. Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women. J Infect. 2018;76(5):449–456. doi:10.1016/j.jinf.2018.01.00629374589
   PubMed Web of Science ®Google Scholar
• Chiarot E, Spagnuolo A, Maccari S, et al. Protective effect of Group B Streptococcus type-III polysaccharide conjugates against maternal colonization, ascending infection and neonatal transmission in rodent models. Sci Rep. 2018;8(1). doi:10.1038/s41598-018-20609-5.
   Web of Science ®Google Scholar
• Kwatra G, Adrian PV, Shiri T, et al. Serotype-specific cell-mediated immunity associated with clearance of homotypic Group B Streptococcus Rectovaginal Colonization in Pregnant Women. J Infect Dis. 2016;213:1923–1926. doi:10.1093/infdis/jiw05627029777
   PubMed Web of Science ®Google Scholar
• Le Doare K, Faal A, Jaiteh M, et al. Association between functional antibody against Group B Streptococcus and maternal and infant colonization in a Gambian cohort. Vaccine. 2017;35(22):2970–2978. doi:10.1016/j.vaccine.2017.04.01328449969
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Maes C, Willekens J, et al. A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women. Vaccine. 2016;34(15):1786–1791. doi:10.1016/j.vaccine.2016.02.04426928074
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Bebia Z, Maes C, et al. Safety and immunogenicity of a second dose of an investigational maternal trivalent Group B streptococcus vaccine in non-pregnant women 4–6 years after a first dose: results from a Phase 2 trial. Clin Infect Dis. pii: ciz73.
   Google Scholar
• Kobayashi M, Schrag SJ, Alderson MR, et al. WHO consultation on group B Streptococcus vaccine development: report from a meeting held on 27–28 April 2016. Vaccine. 2016;37:7307–7314.28017431
   PubMed Web of Science ®Google Scholar
• Lin FC, Philips JB III, Azimi PH, et al. Level of maternal antibody required to protect neonates against early‐onset disease caused by Group B Streptococcus Type Ia: a Multicenter, Seroepidemiology Study. J Infect Dis. 2001;184(8):1022–1028. doi:10.1086/32335011574917
   PubMed Web of Science ®Google Scholar
• Lin FC, Weisman LE, Azimi PH, et al. Level of maternal IgG Anti–Group B Streptococcus Type III antibody correlated with protection of neonates against early‐onset disease caused by this pathogen. J Infect Dis. 2004;190(5):928–934. doi:10.1086/42275615295698
   PubMed Web of Science ®Google Scholar
• Baker CJ, Carey VJ, Rench MA, et al. Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis. 2014;209(5):781–788. doi:10.1093/infdis/jit54924133184
   PubMed Web of Science ®Google Scholar
• Carreras-Abad C, Cochet M, Hall T, et al. Developing a serocorrelate of protection against invasive group B streptococcus disease in pregnant women: a feasibility study. Health Technol Assess. 2019 Dec;23(67):1–40. doi:10.3310/hta23670
   Web of Science ®Google Scholar
• Le Doare K, Kampmann B, Vekemans J, et al. Serocorrelates of protection against infant group B streptococcus disease. Lancet Infect Dis. 2019;19(5):e162–71. doi:10.1016/S1473-3099(18)30659-530683467
   PubMed Web of Science ®Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–2782. doi:10.1016/S0140-6736(16)31921-328100432
   PubMed Web of Science ®Google Scholar
• Pavliakova D, Giardina PC, Moghazeh S, et al. Development and validation of 13-plex luminex-based assay for measuring human serum antibodies to Streptococcus pneumoniae capsular polysaccharides. mSphere. 2018;3(4):e00128–18. doi:10.1128/mSphere.00128-1830089645
   PubMed Web of Science ®Google Scholar
• Buffi G, Galletti B, Stella M, et al. Novel multiplex immunoassays for quantification of IgG against Group B Streptococcus Capsular Polysaccharides in Human Sera. mSphere. 2019;4(4). doi:10.1128/mSphere.00273-19.
   Web of Science ®Google Scholar
• Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal Group B Streptococcal infection. N Engl J Med. 2010;294(14):753–756. doi:10.1056/NEJM197604012941404
   Web of Science ®Google Scholar
• Brigtsen AK, Kasper DL, Baker CJ, Jennings HJ, Guttormsen H. Induction of cross-reactive antibodies by immunization of healthy adults with Types Ia and Ib Group B Streptococcal Polysaccharide–Tetanus Toxoid Conjugate Vaccines. J Infect Dis. 2002;185(9):1277–1284. doi:10.1086/jid.2002.185.issue-912001045
   PubMed Web of Science ®Google Scholar
• Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccin Immunol. 2006;13:165–169. doi:10.1128/CVI.13.2.165-169.2006
   PubMed Web of Science ®Google Scholar
• Fleck RA, Romero-Steiner S, Nahm MH. Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies. Clin Diagn Lab Immunol. 2005;12:19–27. doi:10.1128/CDLI.12.1.19-27.200515642980
   PubMedGoogle Scholar
• Kim KH, Yu J, Nahm MH. Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Clin Diagn Lab Immunol. 2003;10(4):616–621. doi:10.1128/cdli.10.4.616-621.200312853394
   PubMedGoogle Scholar
• Romero-Steiner S, Frasch C, Concepcion N, et al. Multilaboratory evaluation of a viability assay for measurement of opsonophagocytic antibodies specific to the capsular polysaccharides of Streptococcus pneumoniae. Clin Diagn Lab Immunol. 2003;10(6):1019–1024. doi:10.1128/cdli.10.6.1019-1024.200314607861
   PubMedGoogle Scholar
• Choi MJ, Noh JY, Cheong HJ, et al. Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B Streptococcus. Hum Vaccin Immunother. 2018;14(1):67–73. doi:10.1080/21645515.2017.137737928933634
   PubMed Web of Science ®Google Scholar
• Konini A, Kang M, Moghadas SM. Simulating immune interference on the effect of a bivalent glycoconjugate vaccine against Haemophilus influenzae Serotypes “a” and “b.”. Can J Infect Dis Med Microbiol. 2016;2016:1–8. doi:10.1155/2016/5486869
   Web of Science ®Google Scholar
• Borrow R, Dagan R, Zepp F, Hallander H, Poolman J. Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev Vaccin. 2011;10:1621–1631. doi:10.1586/erv.11.142
   PubMed Web of Science ®Google Scholar
• Flores AR, Galloway-Peña J, Sahasrabhojane P, et al. Sequence type 1 group B Streptococcus, an emerging cause of invasive disease in adults, evolves by small genetic changes. Proc Natl Acad Sci U S A. 2015;112(20):6431–6436. doi:10.1073/pnas.150472511225941374
   PubMed Web of Science ®Google Scholar
• Teatero S, Ferrieri P, Martin I, Demczuk W, CGeer A, Fittipaldi N. Serotype distribution, population structure, and antimicrobial resistance of group b streptococcus strains recovered from colonized pregnant women. J Clin Microbiol. 2017;55(2):412–422. doi:10.1128/JCM.01615-1627852675
   PubMed Web of Science ®Google Scholar
• Bellais S, Six A, Fouet A, et al. Capsular switching in group B streptococcus CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development. J Infect Dis. 2012;206(11):1745–1752. doi:10.1093/infdis/jis60523002446
   PubMed Web of Science ®Google Scholar
• Areschoug T, Stålhammar-Carlemalm M, Larsson C, Lindahl G. Group B streptococcal surface proteins as targets for protective antibodies: identification of two novel proteins in strains of serotype V. Infect Immunol. 1999;67(12):6350–6357.10569749
   PubMed Web of Science ®Google Scholar
• Furfaro LL, Chang BJ, Payne MS. Perinatal streptococcus agalactiae epidemiology and surveillance targets. Clin Microbiol Rev. 2018;31. doi:10.1128/CMR.00049-18
   Web of Science ®Google Scholar
• Lindahl G, Stålhammar-Carlemalm M, Areschoug T. Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin Microbiol Rev. 2005;18:102–127. doi:10.1128/CMR.18.1.102-127.200515653821
   PubMed Web of Science ®Google Scholar
• Smith TC, Roehl SA, Pillai P, Li S, Marrs CF, Foxman B. Distribution of novel and previously investigated virulence genes in colonizing and invasive isolates of Streptococcus agalactiae. Epidemiol Infect. 2007;135(6):1046–1054. doi:10.1017/S095026880600751517156495
   PubMed Web of Science ®Google Scholar
• Erdogan S, Fagan PK, Talay SR, et al. Molecular analysis of group B protective surface protein, a new cell surface protective antigen of group B streptococci. Infect Immunol. 2002;70(2):803–811. doi:10.1128/IAI.70.2.803-811.200211796614
   PubMed Web of Science ®Google Scholar
• Maeland JA, Afset JE, Lyng RV, Radtke A. Survey of immunological features of the alpha-like proteins of streptococcus agalactiae. Clin Vaccin Immunol. 2015;22:153–159. doi:10.1128/CVI.00643-14
   Google Scholar
• Lin SM, Zhi Y, Ahn KB, Lim S, Seo HS. Status of group B streptococcal vaccine development. Clin Exp Vaccin Res. 2018;7(1):76–81. doi:10.7774/cevr.2018.7.1.76
   Web of Science ®Google Scholar
• Seo HS, Minasov G, Seepersaud R, et al. Characterization of fibrinogen binding by glycoproteins Srr1 and Srr2 of Streptococcus agalactiae. J Biol Chem. 2013;288(50):35982–35996. doi:10.1074/jbc.M113.51335824165132
   PubMed Web of Science ®Google Scholar
• Seo HS, Mu R, Kim BJ, Doran KS, Sullam PM. Binding of Glycoprotein Srr1 of Streptococcus agalactiae to fibrinogen promotes attachment to brain endothelium and the development of meningitis. PLoS Pathog. 2012;8(10):e1002947. doi:10.1371/journal.ppat.100294723055927
   PubMed Web of Science ®Google Scholar
• Wang NY, Patras KA, Seo HS, et al. Group B streptococcal serine-rich repeat proteins promote interaction with fibrinogen and vaginal colonization. J Infect Dis. 2014;210:982–991. doi:10.1093/infdis/jiu15124620021
   PubMed Web of Science ®Google Scholar
• Lin SM, Jang AY, Zhi Y, et al. Vaccination with a latch peptide provides serotypeindependent protection against group B streptococcus infection in mice. J Infect Dis. 2018;217(1):93–102. doi:10.1093/infdis/jix565
   Web of Science ®Google Scholar
• Bohnsack JF, Widjaja K, Ghazizadeh S, et al. A role for C5 and C5a-ase in the acute neutrophil response to Group B Streptococcal infections. J Infect Dis. 1997;175(4):847–855. doi:10.1086/jid.1997.175.issue-49086140
   PubMed Web of Science ®Google Scholar
• Santillan DA, Andracki ME, Hunter SK. Protective immunization in mice against group B streptococci using encapsulated C5a peptidase. Am J Obstet Gynecol. 2008;198(1):114.e1–114.e6. doi:10.1016/j.ajog.2007.06.003
   Web of Science ®Google Scholar
• Santillan DA, Rai KK, Santillan MK, Krishnamachari Y, Salem AK, Hunter SK. Efficacy of polymeric encapsulated C5a peptidasebased group B streptococcus vaccines in a murine model. Am J Obstet Gynecol. 2011;205:249.e1–249.e8.
   Web of Science ®Google Scholar
• Nuccitelli A, Cozzi R, Gourlay LJ, et al. Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci U S A. 2011;108(25):10278–10283. doi:10.1073/pnas.110659010821593422
   PubMed Web of Science ®Google Scholar
• Edwards MS, Rench MA, Rinaudo CD, et al. Immune responses to invasive group B streptococcal disease in adults. Emerg Infect Dis. 2016;22(11):1877–1883. doi:10.3201/eid2211.16091427767008
   PubMed Web of Science ®Google Scholar
• Madhi SA, Dangor Z, Heath PT, et al. Considerations for a phase-III trial to evaluate a group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of early- and late-onset invasive disease in young-infants. Vaccine. 2013;31:D52–D57. doi:10.1016/j.vaccine.2013.02.02923973347
   PubMed Web of Science ®Google Scholar
• Heath PT, Culley FJ, Jones CE, et al. Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis. Lancet Infect Dis. 2017;17:e223–34. doi:10.1016/S1473-3099(17)30232-328433702
   PubMed Web of Science ®Google Scholar
• JUNO project [homepage on the Internet]. Available from: https://www.sanger.ac.uk/science/collaboration/juno-global-genomic-survey-streptococcus-agalactiae. Accessed 316, 2020.
   Google Scholar
• Heyderman RS, Madhi SA, French N, et al. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. Lancet Infect Dis. 2016;16(5):546–555. doi:10.1016/S1473-3099(15)00484-326869376
   PubMed Web of Science ®Google Scholar
• Jones CE, Calvert A, Le Doare K. Vaccination in pregnancy - Recent developments. Pediatr Infect Dis J. 2018;37(2):191–193. doi:10.1097/INF.000000000000182229135826
   PubMed Web of Science ®Google Scholar
• Dauby N, Chamekh M, Melin P, Slogrove AL, Goetghebuer T. Increased risk of group B streptococcus invasive infection in HIV-exposed but uninfected infants: a review of the evidence and possible mechanisms. Front Immunol. 2016;7. doi:10.3389/fimmu.2016.00505
   Web of Science ®Google Scholar
• Wilder-Smith A, Longini I, Zuber PL, et al. The public health value of vaccines beyond efficacy: methods, measures and outcomes. BMC Med. 2017;15(1). doi:10.1186/s12916-017-0911-8.
   Web of Science ®Google Scholar
• Mohle Boetani JC, Schuchat A, Plikaytis BD, Smith JD, Broome CV. Comparison of prevention strategies for neonatal Group B streptococcal infection: a population-based economic analysis. JAMA J Am Med Assoc. 1993;270(12):1442–1448. doi:10.1001/jama.1993.03510120064032
   Web of Science ®Google Scholar
• Kim SY, Russell LB, Park J, et al. Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa. Vaccine. 2014;32(17):1954–1963. doi:10.1016/j.vaccine.2014.01.06224530145
   PubMed Web of Science ®Google Scholar
• Russell LB, Kim SY, Cosgriff B, et al. Cost-effectiveness of maternal GBS immunization in low-income sub-Saharan Africa. Vaccine. 2017;35(49):6905–6914. doi:10.1016/j.vaccine.2017.07.10829129451
   PubMed Web of Science ®Google Scholar
• Ahmed N, Giorgakoudi K, Usuf E, et al. Potential cost-effectiveness of a maternal Group B streptococcal vaccine in The Gambia. Vaccine. 2020;38(15):3096–3104. doi:10.1016/j.vaccine.2020.02.071.
   Web of Science ®Google Scholar